Soft capsule preparation

Details Soft capsule preparation Soft capsule preparation

2008-01-01

2008-01-01

Tate, Christopher R. (Department: 1655)

Drug, bio-affecting and body treating compositions

Plant material or plant extract of undetermined constitution...

Containing or obtained from leguminosae

Reexamination Certificate

active

10524420

ABSTRACT:
A soft capsule preparation which comprises a dispersion of (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid in a vegetable oil filled in a soft capsule comprising a shell having a light blocking effect. The soft capsule preparation preferably comprises polyoxyethylene sorbitan monooleate and glycerol monostearate and the like as surfactants. As the vegetable oil, soybean oil, sesame oil, a mixture thereof, or the like may be used.

REFERENCES:
patent: 4346109 (1982-08-01), Yamatsu et al.
patent: 4491592 (1985-01-01), Katoh et al.
patent: 4655973 (1987-04-01), Yamatsu et al.
patent: 4757140 (1988-07-01), DeLuca et al.
patent: 4788330 (1988-11-01), Nakamoto et al.
patent: 4841038 (1989-06-01), DeLuca et al.
patent: 4883916 (1989-11-01), Nakamoto et al.
patent: 4888439 (1989-12-01), Yamatsu et al.
patent: 4917829 (1990-04-01), Yamatsu et al.
patent: 4988732 (1991-01-01), Yamatsu et al.
patent: 5852057 (1998-12-01), Muto et al.
patent: 5891470 (1999-04-01), Rinaldi et al.
patent: 6369251 (2002-04-01), Takano et al.
patent: 6984742 (2006-01-01), Tanikawa et al.
patent: 2005/0250671 (2005-11-01), Shidoji et al.
patent: 2006/0063838 (2006-03-01), Shidoji et al.
patent: 2006/0094784 (2006-05-01), Kagawa et al.
patent: 0054732 (1982-06-01), None
patent: 0194693 (1986-09-01), None
patent: 0847754 (1998-06-01), None
patent: 1046630 (2003-03-01), None
patent: 781809 (1957-08-01), None
patent: 54-46821 (1979-04-01), None
patent: 55-22645 (1980-02-01), None
patent: 55-138457 (1980-10-01), None
patent: 63-32058 (1981-04-01), None
patent: 56-140949 (1981-11-01), None
patent: 57-106638 (1982-07-01), None
patent: 58-109415 (1983-06-01), None
patent: 62-77317 (1987-04-01), None
patent: 63-32058 (1988-06-01), None
patent: 63-34855 (1988-07-01), None
patent: 63-166824 (1988-07-01), None
patent: 10-167960 (1998-06-01), None
patent: 2000-122974 (2000-04-01), None
patent: 94/22818 (1994-10-01), None
patent: 01/15702 (2001-03-01), None
patent: 01/80854 (2001-11-01), None
patent: 03/097034 (2003-11-01), None
1996. Muto et al. New England Journal of Medicine. vol. 334. No. 24 pp. 1561-1567.
Nariaki Nakamura et al., “Apoptosis in Human Hepatoma Cell Line Induced by 4,5-Didehydrogeranylgeranoic Acid (Acyclic Retinoid) Via Down-Regulation of Transforming Growth Factor-α,” Biochemical and Biophysical Research Communications, vol. 219, No. 1, pp. 100-104 (1996).
M. Okuno et al., “Retinoids Exacerbate Rat Liver Fibrosis by Inducing the Activation of latent TGF-β in Liver Stellate Cells,” Hepatology (Philadelphia), vol. 26, No. 4, pp. 913-921 (1997).
Di Bisceglie A.M. et al., “Hepatocellular Carcinoma,” Hepatology, vol. 28, No. 4, pp. 1161-1165 (1998).
Ishiwari, K., “The Effects of a Synthetic Retinoid on Phenotypic Expression of Cultured Mesangial Cells,” Kyoto-furitsu Ika Daigaku Zasshi, vol. 106, No. 3, pp. 273-283 (1997).
P. Ellinghaus et al., “Phytanic Acid Activates the Peroxisome Proliferator-Activated Receptor α(PPARα) in Sterol Carrier Protein 2-/Sterol Carrier Protein x-deficient Mice,” J. Biol. Chem., vol. 274, No. 5, pp. 2766-2772 (Jan. 29, 1999).
S.A. Kliewer et al., “Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors α and Γ ,” Proc. Natl. Acad. Sci. U.S.A., vol. 94, No. 9, pp. 4318-4323 (Apr. 1997).
M. Göttlicher et al., “Structural and Metabolic Requirements for Activators of the Peroxisome Proliferator-Activated Receptor,” Biochem. Pharmacol., vol. 46, No. 12, pp. 2177-2184 (1993).
I. Issemann et al., “The peroxisome proliferators-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs,” J. Mol. Endocrinol., vol. 11, No. 1, pp. 37-47 (1993).
G.M. Reaven, “Role of Insulin Resistance in Human Disease,” Diabetes, vol. 37, pp. 1595-1607 (1988).
I. Issemann et al., “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, pp. 645-650 (1990).
J.M. Lehmann et al., “An Antidiabetic Thiozolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor Γ(PPARΓ),” J. Biol. Chem. vol. 270, No. 22, pp. 12953-12956 (1995).
A.R. Saltiel et al., “Thiozolidinediones in the Treatment of Insulin Resistance and Type II Diabetes,” Diabetes, vol. 45, pp. 1661-1669 (1996).
Rinshu Iyaku, “Liver Dysfunction Associated with Troglitazone (Noscal®),” vol. 14, pp. 461-466 (1998).
Remington: The Science and Practice of Pharmacy, Mack Publishing Co., Nineteenth Edition, vol. 1, Chapter 48, “The Introduction of New Drugs”, pp. 795-808 (1995).
K. Tago et al., “A Practical Total Synthesis of Plaunotol via Highly Z-selective Wittig Olefination of α-acetal ketones,” J. Chem. Soc. Perkin Trans. 1, pp. 2073-2078 (2000).
W.C. Still et al., “Direct Synthesis of Z-Unsaturated Esters. A Useful Modification of the Horner-Emmons Olefination,” Tetrahedron Letters, vol. 24, No. 41, pp. 4405-4408 (1983).
T. Kajiwara et al., “Stereoselective Synthesis of Ectocarpene and Its Antipode via Microbiological Asymmetric Hydrolysis,” Agric. Biol. Chem., vol. 45, pp. 1461-1466 (1981).
Chinese Journal of Applied Chemistry, vol. 5, 1988, pp. 70-71.
R. Boden, “A Mild Method for Preparing trans-Alkenes; Crown Ether Catalysis of the Wittig Reaction,” Synthesis, p. 784 (1975).
G. Bellucci et al., “Crown Ether Catalyzed Stereospecific Synthesis of Z- and E-Stilbenes by Wittig Reaction in a Solid-Liquid Two-Phases System,” Tetrahedron Letters, vol. 37, No. 24, pp. 4225-4228 (1996).
G. Bellucci et al., “Crown Ether Catalyzed Stereospecific Synthesis of Z- and E-Stilbenes by Wittig Reaction in a Solid-Liquid Two-Phases System,” Tetrahedron Letters, vol. 37, No. 24, pp. 4225-4228 (1996).
M. Mikolajczyk et al., “Synthesis of α,β-Unsaturated Sulphides, Sulphoxides, and Sulphones by the Horner-Wittig Reaction in Two-Phase System Catalysed by Quaternary Ammonium Salts and Crown Ethers,” Synthesis, pp. 278-280 (1975).
Izv. Akad. Nauk SSSR, Khim., 1990, pp. 2544-2550.
Izv. Akad. Nauk SSSR, Khim., 1988, pp. 2382-2385.
Izv. Akad. Nauk SSSR, Khim., 1988, pp. 2377-2382.
R.N. Gedye et al., “The Stereochemistry of the Wittig Reactions of Allylic Phosphroranes and Phosponate Esters with Aldehydes,” Can. J. Chem., vol. 55, pp. 1218-1228 (1977).
K. Ashizawa et al., “The Crystal Structure of 3,7,11,15-Tetramethyl-2,4,6,10,14- All Trans-Hexadecapentaenoic Acid (E-5166),” Chem. Pharm. Bull., vol. 33, No. 7, pp. 3062-3064 (1985).
English language Abstract of JP 56-140949.
English language Abstract of JP 57-106638.
New Eng. J. Med., 1996, vol. 334, No. 24, pp. 1561-1567.
New Eng. J. Med., 1999, vol. 340, No. 13, pp. 1046-1047.
J. Chem. Soc. (C), 1966, pp. 2154-2165.
English Language Abstract of JP 56-140949.
English Language Abstract of JP 10-167960.
English Language Abstract JP 55-22645.
English Language Abstract of JP 58-109415.
English Language Abstract of JP 63-166824.
English Language Abstract of JP 62-77317.
English Language Abstract of JP 54-46821.
English Language of JP 55-138457.

Affiliated with

Also associated with

Rating

Soft capsule preparation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Soft capsule preparation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soft capsule preparation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3944098